This article is more than 5 years old. Information may no longer be current.
Baxter, Mayo Clinic collaborate on new center of excellence for kidney care
Baxter International Inc. and Mayo Clinic are collaborating on plans for a renal care center of excellence at Mayo’s Jacksonville, Florida Campus. The center will serve patients across the continuum of renal care, the health care companies said, from chronic kidney disease management through transplant, with a focus on improving outcomes.
“The collaboration between Mayo Clinic and Baxter combines the best of our clinical, research and innovation expertise, and is rooted in the shared goal to improve the way we care for patients with serious and complex illnesses,” Gianrico Farrugia, MD, CEO of Mayo Clinic in Florida and president-elect of Mayo Clinic, said in a press release from Baxter. “We are excited to establish this new renal care center of excellence with Baxter.”
The Mayo Clinic Dialysis Center currently offers the Chronic Kidney Disease Clinic, home dialysis training and support for both home hemodialysis and peritoneal dialysis. In-center hemodialysis is also available.
Baxter Renal Care Services brings its experience of caring for more than 25,000 patients through its clinics across Asia, Europe and Latin America. These clinics often feature a successful CKD program focused on slowing the progression of kidney disease, as well as Baxter’s latest technologies to support patients’ clinical and lifestyle needs.
“We firmly believe there is a path to better care for kidney patients, which starts by managing the disease before dialysis is required and through simpler, more effective innovations,” Laura Angelini, general manager of Baxter’s renal care business, said in the release. “Our collaboration with Mayo Clinic will allow us to go even further in helping to establish transformative care.”
The dialysis clinic collaboration is the first launched initiative from the Baxter and Mayo Clinic 5-year agreement announced in 2017, allowing the two health care companies to bring together their respective clinical and development expertise. The primary emphasis of the broader agreement focuses on new research and development projects to advance innovation across different therapeutic areas where there are high unmet patient needs, such as renal disease. The initial agreement is for a 5-year period, with a 5-year renewal option, according to the press release.
Reference: